A Phase 3 interventional study of Denosumab in Castrate-resistant Prostate Cancer, sponsored by Amgen. Completed at 9 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.
Among the 10 studies testing denosumab in Prostatic Neoplasms, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 8 in phase 3, and was the 7th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 324 across the 10 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
23 studies in Prostatic Neoplasms by Amgen: 4 open now, 7 under way, 2 of them phase 3. Of 15 finished, 11 (73%) have results posted.
Among the 23 studies in Prostatic Neoplasms by Amgen, this one is the 21st largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2011, is one of 9 in phase 3, and was the 13th registered.
Amgen’s Prostatic Neoplasms studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing denosumab in Prostatic Neoplasms, from their registry updates:
Among Amgen’s 23 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a multi-national, multi-center, open-label, single-arm extension study for the prolongation of bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer. Patients currently participating in the phase 3 study 20050147 (NCT00286091) will be offered this study if a positive benefit:risk compared with placebo is determined in the 20050147 study. The primary endpoint of the 20050147 study is bone metastases-free survival determined by the time to first occurrence of bone metastases (either symptomatic or asymptomatic) or death from any cause. Participants will receive open-label denosumab administered once every 4 weeks (Q4W) subcutaneously (SC) until they developed a bone metastasis or for up to 3 years, whichever comes first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received denosumab 120 mg subcutaneously every 4 weeks for up to 3 years in this open-label extension study.
Biological: Denosumab
Administered by subcutaneous injection
Also known as: XGEVA®
Number of Participants With Treatment-emergent Adverse Events (AEs) and Deaths
A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard. The adverse event severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, according to the following: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The investigator assessed whether each adverse event was possibly related to the investigational product (IP).
Time frame: From the first dose of open-label denosumab until 4 weeks after the last; maximum time on study was 37 months. Follow-up survival information was collected for up to 3 years after the last dose of blinded investigation product in the 20050147 study.
Percent Change From Baseline in Laboratory Values
Time frame: Baseline and Week 49
Number of Participants With Anti-denosumab Neutralizing Antibody Formation
Time frame: 3 years
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work); 2 = Ambulatory and capable of all self care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair; 5 = Dead.
Time frame: Baseline and Week 49
This was a single-arm, open-label extension (OLE) phase of a phase 3, randomized, double-blind study (Study 20050147; NCT00286091) comparing denosumab with placebo on prolonging bone metastasis-free survival in men with hormone-refractory (androgen independent) prostate cancer.
| Milestone | Placebo/Denosumab | Denosumab/Denosumab |
|---|---|---|
| Started | 11 | 7 |
| Completed | 2 | 2 |
| Not completed | 9 | 5 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Disease progression | 1 | 1 |
| Withdrew: Physician decision | 5 | 0 |
| Withdrew: Death | 2 | 0 |
A serious adverse event is defined as an adverse event that meets at least one of the following serious criteria: • fatal, • life threatening, • requires in-patient hospitalization or prolongation of existing hospitalization, • results in persistent or significant disability/incapacity, • congenital anomaly/birth defect, and/or • other significant medical hazard. The adverse event severity grading scale used was the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, according to the following: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The investigator assessed whether each adverse event was possibly related to the investigational product (IP).
| participants | Placebo/Denosumab | Denosumab/Denosumab |
|---|---|---|
| Any adverse event (AE) | 11 | 7 |
| Serious adverse event | 7 | 4 |
| Fatal adverse event | 2 | 0 |
| AE leading to study discontinuation | 2 | 1 |
| AE leading to IP discontinuation | 4 | 1 |
| CTCAE Grade 3, 4, or 5 | 6 | 2 |
| AE related to investigational product (IP) | 2 | 3 |
| Serious AE related to IP | 0 | 2 |
| Fatal AE related to IP | 0 | 0 |
| AE related to IP leading to study discontinuation | 1 | 1 |
| AE related to IP leading to IP discontinuation | 1 | 1 |
| AE related to IP and CTCAE Grade 3, 4, or 5 | 0 | 1 |
| Deaths | 4 | 1 |
| Deaths on study | 2 | 0 |
| Deaths during the safety follow-up | 2 | 1 |
| percent change | Placebo/Denosumab | Denosumab/Denosumab |
|---|---|---|
| Albumin-adjusted Calcium | -0.9 ± 2.5 | 1.1 ± 3.1 |
| Alkaline Phosphatase | -23.8 ± 21.8 | -1.6 ± 20.5 |
| Creatinine | 16.3 ± 31.5 | 2.4 ± 5.8 |
| Phosphorus | -2.6 ± 25.2 | 0.0 ± 10.4 |
| participants | Placebo/Denosumab | Denosumab/Denosumab |
|---|---|---|
| Number of Participants With Anti-denosumab Neutralizing Antibody Formation | 0 | 0 |
A scale used to assess how a patient's disease is progressing, assess how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work); 2 = Ambulatory and capable of all self care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair; 5 = Dead.
| participants | Placebo/Denosumab | Denosumab/Denosumab |
|---|---|---|
| 4-point increase in PS | 0 | 0 |
| 3-point increase in PS | 0 | 0 |
| 2-point increase in PS | 0 | 0 |
| 1-point increase in PS | 0 | 1 |
| No change | 10 | 5 |
| 1-point decrease in PS | 0 | 0 |
| 2-point decrease in PS | 0 | 0 |
Collected over 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo/ Denosumab 120 mg Q4W | — | 7/11 (63.6%) | 11/11 (100%) |
| Denosumab/ Denosumab 120 mg Q4W | — | 4/7 (57.1%) | 6/7 (85.7%) |
| Event | Placebo/ Denosumab 120 mg Q4W | Denosumab/ Denosumab 120 mg Q4W |
|---|---|---|
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 0/11 | 2/7 |
| Urinary tract infectionInfections and infestations | 2/11 | 0/7 |
| Metastatic painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/11 | 0/7 |
| HydronephrosisRenal and urinary disorders | 2/11 | 0/7 |
| Urinary retentionRenal and urinary disorders | 2/11 | 0/7 |
| PhimosisCongenital, familial and genetic disorders | 0/11 | 1/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/11 | 1/7 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/11 | 1/7 |
| Mitral valve incompetenceCardiac disorders | 1/11 | 0/7 |
| Myocardial infarctionCardiac disorders | 1/11 | 0/7 |
| Event | Placebo/ Denosumab 120 mg Q4W | Denosumab/ Denosumab 120 mg Q4W |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 4/11 | 0/7 |
| Urinary tract infectionInfections and infestations | 3/11 | 2/7 |
| Prostatic specific antigen increasedInvestigations | 2/11 | 2/7 |
| AnaemiaBlood and lymphatic system disorders | 3/11 | 0/7 |
| FatigueGeneral disorders | 3/11 | 0/7 |
| Oedema peripheralGeneral disorders | 3/11 | 1/7 |
| DizzinessNervous system disorders | 3/11 | 0/7 |
| HaematuriaRenal and urinary disorders | 3/11 | 1/7 |
| DiarrhoeaGastrointestinal disorders | 2/11 | 0/7 |
| VomitingGastrointestinal disorders | 2/11 | 1/7 |
| Age, Continuous(years) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Mean | 71.6 ± 4.3 | 70.3 ± 7.4 | 71.1 ± 5.6 |
| Sex: Female, Male(Participants) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 11 | 7 | 18 |
| Race/Ethnicity, Customized(participants) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| White or Caucasian | 11 | 7 | 18 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Grade 0 | 7 | 5 | 12 |
| Grade 1 | 4 | 1 | 5 |
| Grade 2 | 0 | 1 | 1 |
| Grade 3 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 |
| Albumin-adjusted calcium(mmol/L) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Mean | 2.44 ± 0.10 | 2.42 ± 0.04 | 2.43 ± 0.08 |
| Creatinine(umol/L) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Mean | 88.40 ± 14.25 | 89.66 ± 23.63 | 88.89 ± 17.80 |
| Phosphorus(mmol/L) | Placebo/Denosumab | Denosumab/Denosumab | Total |
|---|---|---|---|
| Mean | 1.09 ± 0.22 | 1.01 ± 0.24 | 1.06 ± 0.22 |
The record gives a start of Jan 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab